Unileap Biologics

Unileap Biologics is a clinical-stage biotechnology company focused on developing next-generation multi-specific antibody therapeutics for cancer and autoimmune diseases. The company utilizes its proprietary Uni-Leap platform to design and engineer complex biologics, including bispecific and trispecific antibodies, that can precisely modulate the immune system. Its lead program, ULB101, is a bispecific antibody targeting PD-L1 and 4-1BB, designed to enhance anti-tumor activity while minimizing systemic toxicity. Headquartered in Hangzhou with R&D facilities in Shanghai, Unileap is advancing a diverse pipeline of candidates aimed at addressing significant unmet medical needs in oncology. The company's approach combines deep expertise in protein engineering with a focus on clinically validated pathways to create differentiated therapeutic options.